Date: 2018-07-13
Type of information: Nomination
Compound: chief technology officer
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 13, 2018, Sangamo Therapeutics announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.
- Dr. Holmes joined Sangamo in 2001 as a senior scientist and over the years has been promoted to lead many of Sangamo's research programs. Along with Dr. Rebar and other Sangamo scientists, Dr. Holmes made important contributions to the development of zinc finger proteins for therapeutic, research and agricultural applications. He was named Chief Technology Officer earlier in 2018.
- Dr. Rebar joined Sangamo in 1998, and over the last 20 years he has led the development of the company's zinc finger protein platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.
Financial terms:
Latest news:
Is general: Yes
